论文部分内容阅读
支气管哮喘(以下简称哮喘)是一种异质性疾病,嗜酸粒细胞和中性粒细胞等在内的多种炎症细胞及其组分均参与了哮喘慢性气道炎症的形成,并在此基础上导致气道高反应性和可逆性气道阻塞,临床上患者表现为喘息、气促、咳嗽等症状[1]。除消除症状外,减少急性发作和保护肺功能是哮喘治疗的长期目标,以吸入糖皮质激素为主的气道抗炎药物是目前哮喘控制最有效的措施。鉴于慢性气道炎
Bronchial asthma (hereinafter referred to as asthma) is a heterogeneous disease, a variety of inflammatory cells including eosinophils and neutrophils, and their components are involved in the formation of chronic airway inflammation in asthma, and in this Based on the resulting airway hyperresponsiveness and reversible airway obstruction, the clinical manifestations of wheezing, shortness of breath, cough and other symptoms [1]. In addition to eliminating symptoms, the reduction of acute episodes and the protection of lung function are the long-term goals of asthma treatment. Corticosteroid-based airway anti-inflammatory drugs are the most effective measures of asthma control. Given chronic airway inflammation